title: Theranostic tumor homing nanocarriers for the treatment of lung cancer.
abstract: The drugs/strategies to selectively inhibit tumor blood supply have generated interest in recent years for enhancement of cancer therapeutics. The objective of this study was to formulate tumor homing PEGylated CREKA peptide conjugated theranostic nanoparticles of DIM-C-pPhC6H5 (DIM-P) and investigate in vivo antitumor activity as well as evaluate the targeted efficiency to lung tumors using imaging techniques. DIM-P loaded Nanoparticles (NCs-D) were prepared using lipids, and DOGS-NTA-Ni and the surface of NCs-D were modified with PEGylated CREKA peptide (PCNCs-D). PCNCs-D showed 3 fold higher binding to clotted plasma proteins in tumor vasculature compared to NCs-D. PCNCs-D showed 26%±4% and 22%±5% increase in tumor reduction compared to NCs-D in metastatic and orthotopic models respectively. In-vivo imaging studies showed ~40 folds higher migration of PCNCs-Di in tumor vasculature than NCs-Di. Our studies demonstrate the role of PCNCs-D as theranostic tumor homing drug delivery and imaging systems for lung cancer diagnosis and treatment.
  
  
  BACKGROUND
  This study demonstrates a very efficient delivery system to address lung cancer growth through blood supply inhibition.
authors.affiliation: College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA.
authors.forename: Apurva R
authors.initials: AR
authors.lastname: Patel
authors.affiliation: Department of Pharmaceutical Sciences, College of Pharmacy, University of Hawai'i at Hilo, Hilo, HI, USA.
authors.forename: Mahavir B
authors.initials: MB
authors.lastname: Chougule
authors.affiliation: Calipers-Life Sciences & Technology, A Perkin Elmer Company, Alameda, CA, USA.
authors.forename: Ed
authors.initials: E
authors.lastname: Lim
authors.affiliation: Calipers-Life Sciences & Technology, A Perkin Elmer Company, Alameda, CA, USA.
authors.forename: Kevin P
authors.initials: KP
authors.lastname: Francis
authors.affiliation: Institute of Biosciences and Technology, Texas A&M University, Houston, TX, USA.
authors.forename: Stephen
authors.initials: S
authors.lastname: Safe
authors.affiliation: College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA. Electronic address: mandip.sachdeva@famu.edu.
authors.forename: Mandip
authors.initials: M
authors.lastname: Singh
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D051379:Mice; D008819:Mice, Nude; D053758:Nanoparticles / Q000737:chemistry*; D009842:Oligopeptides / Q000737:chemistry; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D009842:Oligopeptides; C542438:cysteinyl-arginyl-glutamyl-lysyl-alanyl
keywords: Cancer treatment; In-vivo imaging; Nanoparticles; Targeted delivery; Theranostic; Tumor homing